Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John E Janik

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|April 6, 2011
Tumor markers in hairy cell leukemiaJohn E Janik
Journal of Immunology (Baltimore, Md. : 1950)|April 20, 2006
Comment on "Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade"Deirdre O'Mahony, John E Janik
Oncology (Williston Park, N.Y.)|February 4, 2010
Survivin(g) adult T-cell leukemia/lymphomaJohn E Janik, John C Morris
Leukemia & Lymphoma|June 20, 2007
Therapeutic immunotoxins for lymphoid malignancies: the end of the beginningJohn C Morris, John E Janik
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2011
Brentuximab Vedotin (SGN-35)Jessica Katz, John E Janik, Anas Younes
Journal of Immunotoxicology|June 24, 2008
Receptor-directed therapy of T-cell leukemias and lymphomasJohn C Morris, Thomas A Waldmann, John E Janik
British Journal of Haematology|December 21, 2002
Common expression of an unusual CD45 isoform on T cells from patients with large granular lymphocyte leukaemia and autoimmune lymphoproliferative syndromeJack J H Bleesing, John E Janik, Thomas A Fleisher
Cancer Journal (Sudbury, Mass.)|April 25, 2009
Role of chemotherapy in Hodgkin's lymphomaPamela Seam, John E Janik, Dan L Longo, et al.
Lancet (London, England)|March 18, 2008
Mycosis fungoides and Sézary syndromeSam T Hwang, John E Janik, Elaine S Jaffe, et al.
Gynecologic Oncology Reports|October 21, 2020
Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinomaAndrey Moiseyenko, Franco Muggia, Thomas Condamine, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|April 6, 2011
Tumor markers in hairy cell leukemiaJohn E Janik
Journal of Immunology (Baltimore, Md. : 1950)|April 20, 2006
Comment on "Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade"Deirdre O'Mahony, John E Janik
Oncology (Williston Park, N.Y.)|February 4, 2010
Survivin(g) adult T-cell leukemia/lymphomaJohn E Janik, John C Morris
Leukemia & Lymphoma|June 20, 2007
Therapeutic immunotoxins for lymphoid malignancies: the end of the beginningJohn C Morris, John E Janik
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2011
Brentuximab Vedotin (SGN-35)Jessica Katz, John E Janik, Anas Younes
Journal of Immunotoxicology|June 24, 2008
Receptor-directed therapy of T-cell leukemias and lymphomasJohn C Morris, Thomas A Waldmann, John E Janik
British Journal of Haematology|December 21, 2002
Common expression of an unusual CD45 isoform on T cells from patients with large granular lymphocyte leukaemia and autoimmune lymphoproliferative syndromeJack J H Bleesing, John E Janik, Thomas A Fleisher
Cancer Journal (Sudbury, Mass.)|April 25, 2009
Role of chemotherapy in Hodgkin's lymphomaPamela Seam, John E Janik, Dan L Longo, et al.
Lancet (London, England)|March 18, 2008
Mycosis fungoides and Sézary syndromeSam T Hwang, John E Janik, Elaine S Jaffe, et al.
Gynecologic Oncology Reports|October 21, 2020
Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinomaAndrey Moiseyenko, Franco Muggia, Thomas Condamine, et al.
Pageof 7